FindTrial
Sign In

Application of "Fog Mirror Imaging +Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children

Application of "Fog Mirror Imaging = Dot Matrix Defocus Technology" Vision Management Lenses in Myopia Control for Adolescents and Children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118110
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-04
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

myopia

Interventions

Dual-control Lens Group:Wearing bi-focal lenses
Xinle Learning (DIMS) Lens group:Wearing New LuxVision (DIMS) lenses

Sponsors

The First People's Hospital of Xuzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Age 6 to 12 years, any gender; 2. Refractive status meets the following conditions: (1) After cycloplegia, computer-based refraction shows both eyes with an equivalent spherical diopter between -0.50D and -6.00D (including -0.50D and -6.00D); (2) After cycloplegia, computer-based refraction shows astigmatism in both eyes not exceeding 2.0D; (3) After cycloplegia, computer-based refraction shows anisometropia in both eyes less than 2.00D; 3. Intraocular pressure in both eyes is normal (greater than or equal to 10 mmHg, less than or equal to 21 mmHg); 4. Best-corrected distance visual acuity in either eye is equal to or better than 0.8; 5. No amblyopia or any other pathological changes in either eye; 6. The patient fully understands and voluntarily participates in this study, and the informed consent form is signed by both the patient and the parent/guardian.

Exclusion criteria

Exclusion criteria: 1. Any ocular or systemic diseases that may be related to the development of myopia or affect refractive status (such as congenital cataract, retinopathy of prematurity, Marfan syndrome, diabetes, etc.); 2. Presence of manifest strabismus or obvious binocular visual function abnormalities; 3. Unwillingness to cooperate with visits; 4. Other situations where the researcher determines the patient is not suitable for inclusion; 5. Currently participating in other clinical trials that may affect this study, or having used other myopia control methods within the past three months, such as low-concentration atropine, orthokeratology lenses, red light therapy, etc.

Design outcomes

Primary

MeasureTime frame
Axial length;Spherical Equivalent, SE ;—

Countries

China

Contacts

Public ContactLi Ying

Xuzhou Municipal Hospital Affiliated to Xuzhou Medical University

liying20220318@163.com+86 151 6213 0727

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026